• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    2/26/24 1:57:55 PM ET
    $ACON
    $AEHL
    $AGTI
    $AKLI
    Medical Specialities
    Health Care
    Building Materials
    Industrials
    Get the next $ACON alert in real time by email

    Shares of Freshpet, Inc. (NASDAQ:FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results.

    Freshpet posted quarterly earnings of 31 cents per share, beating market estimates of 5 cents per share. The company’s quarterly sales came in at $215.42 million versus expectations of $204.36 million.

    Freshpet shares gained 15.5% to $106.29 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Akili, Inc. (NASDAQ:AKLI) shares jumped 126% to $0.5009 after the company reported positive results from Shionogi's Phase 3 clinical trial of localized version of Akili's EndeavorRx® for Pediatric ADHD patients in Japan.
    • ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) climbed 126% to $1.81 after surging over 30% on Friday.
    • MicroCloud Hologram Inc. (NASDAQ:HOLO) gained 107% to $13.71 after tumbling 40% on Friday.
    • Neptune Wellness Solutions Inc. (NASDAQ:NEPT) rose 54.6% to $0.49.
    • Interactive Strength Inc. (NASDAQ:TRNR) surged 32.2% to $0.8701 after the company announced it has entered into an exclusive worldwide distribution agreement with WOODWAY to sell and distribute CLMBR.
    • Agiliti, Inc. (NASDAQ:AGTI) gained 29.4% to $9.89 after the company announced it will be taken private by THL Partners.
    • Krystal Biotech, Inc. (NASDAQ:KRYS) surged 28.8% to $143.34 after the company reported better-than-expected financial results.
    • R1 RCM Inc. (NYSE:RCM) surged 26.7% to $14.06 after the company received an acquisition offer for the company valued at $13.75 per share.
    • Butterfly Network, Inc. (NASDAQ:BFLY) gained 26.3% to $1.2880.
    • Altimmune, Inc. (NASDAQ:ALT) surged 22.1% to $11.24.
    • Milestone Pharmaceuticals Inc. (NASDAQ:MIST) gained 21.3% to $2.10 after the company announced plans to resubmit the New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT).
    • Ocugen, Inc. (NASDAQ:OCGN) climbed 18.9% to $0.9451.
    • ImmunityBio, Inc. (NASDAQ:IBRX) gained 18% to $ 4.1250.
    • Li Auto Inc. (NASDAQ:LI) rose 16.2% to $40.44 after the company reported fourth-quarter financial results above estimates and issued first-quarter guidance.
    • Nuwellis, Inc. (NASDAQ:NUWE) shares rose 16.1% to $0.7101.
    • SkyWater Technology, Inc. (NASDAQ:SKYT) gained 15.4% to $10.98.
    • ImmunityBio, Inc. (NASDAQ:IBRX) gained 14.3% to $3.9999 after dipping 33% on Friday.
    • Celldex Therapeutics, Inc. (NASDAQ:CLDX) surged 13.9% to $43.00 following strong quarterly sales.
    • Polestar Automotive Holding UK PLC (NASDAQ:PSNY) gained 13.4% to $1.4850.
    • Itron, Inc. (NASDAQ:ITRI) rose 12.3% to $84.11 after the company reported fourth-quarter financial results and issued first-quarter guidance above estimates.
    • HashiCorp, Inc. (NASDAQ:HCP) gained 11.8% to $24.77 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $23 to $30.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) jumped 11.2% to $26.67.
    • NeuBase Therapeutics, Inc. (NASDAQ:NBSE) shares surged 10.5% to $0.83. Neubase Therapeutics, on Feb. 22, said board determined for company to dissolve, liquidate and distribute to stockholders its available assets.
    • Carmell Corporation (NASDAQ:CTCX) rose 9.9% to $2.47. Carmell announced product development has been completed for Gold Limited Edition Exclusive launch in March 2024.
    • Domino's Pizza, Inc. (NYSE:DPZ) gained 8.2% to $469.01 after the company’s fourth quarter 2023 earnings surpassed Wall Street expectations, raised its quarterly dividend, and announced an additional share buyback plan.
    • NIO Inc. (NYSE:NIO) rose 6.5% to $5.75. The company on Monday announced that it entered into a technology license agreement with Forseven Limited.
    • Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares gained 4.3% to $13.44 after the company announced FDA approval of its arthritis treatment.

    Losers

    • Aclarion, Inc. (NASDAQ:ACON) shares fell 62.5% to $0.34 after the company priced its public offering of 5.175 million units. Each unit includes one share of common stock (or a pre-funded warrant), and two common warrants.
    • Venus Concept Inc. (NASDAQ:VERO) dipped 28.8% to $0.93 after the company announced a $1.2 million registered direct offering at $1.465 per share.
    • DIH Holding US, Inc. (NASDAQ:DHAI) fell 28.3% to $0.79.
    • ThermoGenesis Holdings, Inc. (NASDAQ:THMO) dipped 27.5% to $0.7601.
    • Intuitive Machines, Inc. (NASDAQ:LUNR) fell 25.1% to $7.18 after the company said its lunar lander may have tipped over upon landing on the moon.
    • Semilux International Ltd. (NASDAQ:SELX) declined 24.4% to $0.8615.
    • Brera Holdings PLC (NASDAQ:BREA) fell 21.8% to $0.8601.
    • Antelope Enterprise Holdings Limited (NASDAQ:AEHL) dipped 21.8% to $1.50. Antelope Enterprise announced closing of $1.3 million registered direct offering and private placement.
    • NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) fell 19.4% to $1.5399. NGM Bio has entered into a definitive agreement and plan of merger with certain affiliates of the Column Group, LP.
    • Telesis Bio, Inc. (NASDAQ:TBIO) shares fell 17.8% to $0.6401. Telesis Bio shares jumped 72% on Friday after the company was granted EUR Patent #3503915 for "Genetically Engineered Vibrio Natriegens (Host Organism For Cloning And Manipulating DNA)."
    • Beneficient (NASDAQ:BENF) fell 17% to $0.1640. On Feb. 13, Beneficient posted a third-quarter loss of $1.98 per share.
    • Dogness (International) Corporation (NASDAQ:DOGZ) fell 17% to $6.14.
    • AtlasClear Holdings, Inc. (NYSE:ATCH) shares fell 11.2% to $2.3450 after jumping over 131% on Friday.
    • Jin Medical International Ltd. (NASDAQ:ZJYL) declined 11.2% to $6.30.
    • Roma Green Finance Limited (NASDAQ:ROMA) fell 9.9% to $1.4599 after tumbling 11% on Friday.
    • Surgery Partners, Inc. (NASDAQ:SGRY) dipped 7.8% to $30.43 following weak quarterly sales.
    • World Acceptance Corporation (NASDAQ:WRLD) fell 7% to $120.71. World Acceptance recently reported better-than-expected third-quarter financial results.

     

    Now Read This: Intuit To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AEHL
    $AGTI
    $AKLI

    CompanyDatePrice TargetRatingAnalyst
    Celldex Therapeutics Inc.
    $CLDX
    3/23/2026$44.00Peer Perform → Outperform
    Wolfe Research
    Freshpet Inc.
    $FRPT
    3/20/2026$80.00Perform → Outperform
    Oppenheimer
    Altimmune Inc.
    $ALT
    3/18/2026$12.00Buy
    Truist
    Ocugen Inc.
    $OCGN
    3/17/2026$12.00Buy
    Canaccord Genuity
    Li Auto Inc.
    $LI
    3/17/2026$19.00Buy → Neutral
    Goldman
    NIO Inc.
    $NIO
    3/13/2026$6.80Hold → Buy
    HSBC Securities
    ImmunityBio Inc.
    $IBRX
    3/12/2026$13.00Buy
    BTIG Research
    Ocugen Inc.
    $OCGN
    3/11/2026$10.00Outperform
    Oppenheimer
    More analyst ratings

    $ACON
    $AEHL
    $AGTI
    $AKLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celldex Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Celldex Therapeutics from Peer Perform to Outperform and set a new price target of $44.00

    3/23/26 8:22:59 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Freshpet upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Freshpet from Perform to Outperform and set a new price target of $80.00

    3/20/26 8:29:01 AM ET
    $FRPT
    Packaged Foods
    Consumer Staples

    Truist initiated coverage on Altimmune with a new price target

    Truist initiated coverage of Altimmune with a rating of Buy and set a new price target of $12.00

    3/18/26 4:00:13 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AEHL
    $AGTI
    $AKLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtlasClear Announces Commencement of Dawson James Clearing Operations

    NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- AtlasClear Holdings, Inc. (NYSE:ATCH) ("AtlasClear" or the "Company"), a financial services company building modern clearing, custody, and trading infrastructure, today announced that Dawson James Securities, Inc. has commenced clearing operations through Wilson-Davis & Co., Inc., AtlasClear's wholly owned self-clearing broker-dealer subsidiary. The onboarding of Dawson James represents the first major introducing broker integration on Wilson-Davis' enhanced clearing platform. During the integration process, the Company completed targeted enhancements to its clearing technology stack to support multi-client scalability. These infrastructure upg

    3/23/26 4:05:00 PM ET
    $ATCH
    Finance: Consumer Services
    Finance

    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

    Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut

    3/23/26 7:30:00 AM ET
    $KRYS
    $PVLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

    MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026. KOLs leading the webcast include: Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocu

    3/23/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AEHL
    $AGTI
    $AKLI
    SEC Filings

    View All

    SEC Form DEFA14A filed by Itron Inc.

    DEFA14A - ITRON, INC. (0000780571) (Filer)

    3/23/26 12:37:54 PM ET
    $ITRI
    Electrical Products
    Industrials

    SEC Form DEF 14A filed by Itron Inc.

    DEF 14A - ITRON, INC. (0000780571) (Filer)

    3/23/26 12:36:50 PM ET
    $ITRI
    Electrical Products
    Industrials

    Ocugen Inc. filed SEC Form 8-K: Other Events

    8-K - Ocugen, Inc. (0001372299) (Filer)

    3/20/26 8:00:18 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AEHL
    $AGTI
    $AKLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Sandoval David I.

    3 - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    3/23/26 6:51:28 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Manko Steve

    4/A - SkyWater Technology, Inc (0001819974) (Issuer)

    3/23/26 5:01:39 PM ET
    $SKYT
    Semiconductors
    Technology

    SEC Form 4 filed by Crain Timothy Price Ii

    4 - Intuitive Machines, Inc. (0001844452) (Issuer)

    3/23/26 5:00:02 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    $ACON
    $AEHL
    $AGTI
    $AKLI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AEHL
    $AGTI
    $AKLI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director George Walter N. bought $49,795 worth of shares (630 units at $79.04), increasing direct ownership by 1% to 47,157 units (SEC Form 4)

    4 - Freshpet, Inc. (0001611647) (Issuer)

    2/26/26 4:07:13 PM ET
    $FRPT
    Packaged Foods
    Consumer Staples

    $ACON
    $AEHL
    $AGTI
    $AKLI
    Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

    Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut

    3/23/26 7:30:00 AM ET
    $KRYS
    $PVLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Surgery Partners, Inc. Names Lloyd Dean to Board of Directors

    BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company") recently announced that Lloyd Dean has been appointed to serve as an independent director on its Board of Directors. Mr. Dean is the former Chief Executive Officer of CommonSpirit Health, one of the largest nonprofit health systems in the United States, with 142 hospitals, over 1,000 care sites, 25,000 physicians, and 150,000 employees across 21 states. From 2019 to 2022, he led the formation and integration of CommonSpirit, advancing clinical quality, operational performance, and community health initiatives at national scale. Prior to CommonSpirit, Mr. Dean ser

    3/12/26 6:12:07 PM ET
    $SGRY
    Hospital/Nursing Management
    Health Care

    Beneficient Appoints Mack H. Hicks to Board of Directors

    DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Beneficient (NASDAQ:BENF), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced the appointment of Mack H. Hicks as a member of the Company's Board of Directors (the "Board"). Mr. Hicks currently serves as Chief Executive Officer of Hicks Holdings LLC, the Dallas-based family office with operating private equity and real estate investment businesses founded by his late father and private equity pioneer, Thomas O. Hicks, who served as Chairman of the Board of Beneficient until his passing in December of 2025. Mr. Hicks also

    3/12/26 7:30:00 AM ET
    $BENF
    Finance: Consumer Services
    Finance

    $ACON
    $AEHL
    $AGTI
    $AKLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Carmell Corporation

    SC 13G/A - Carmell Corp (0001842939) (Subject)

    12/6/24 4:16:05 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by R1 RCM Inc.

    SC 13D/A - R1 RCM Inc. /DE (0001910851) (Subject)

    11/22/24 4:06:56 PM ET
    $RCM
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Intuitive Machines Inc.

    SC 13D/A - Intuitive Machines, Inc. (0001844452) (Subject)

    11/20/24 5:01:02 PM ET
    $LUNR
    Industrial Machinery/Components
    Industrials

    $ACON
    $AEHL
    $AGTI
    $AKLI
    Financials

    Live finance-specific insights

    View All

    Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

    MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026. KOLs leading the webcast include: Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocu

    3/23/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

    FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1Company to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE

    3/20/26 7:12:14 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Releases Q1 2026 Aide Memoire

    TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the "Investors" page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of first quarter 2026 results, which are expected to be released on Wednesday, April 29, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Indust

    3/19/26 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care